{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-116443","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.839709+00:00","generated_at":"2026-05-22T02:00:20.422522+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kymera Q1 net loss $65.6M, cash $775M; unveils oral IRF5 degrader KT-579; STAT6 data June","bullets":["Net loss $65.6M (Q1 2025) vs $48.6M (Q1 2024); collab revenue $22.1M incl $20M Sanofi milestone.","Cash $775M as of Mar 31, 2025; runway extended into H1 2028.","KT-621 (STAT6) Ph1 SAD/MAD healthy volunteer data due June 2025; BroADen Ph1b in AD started, data 4Q25.","New oral IRF5 degrader KT-579 unveiled; IND-enabling ongoing, Phase 1 expected early 2026.","Strategic decision to not advance KT-295 (TYK2) into clinic; focus on STAT6 and IRF5."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-116443","json":"https://secwatch.observer/filing/0001193125-25-116443.json","markdown":"https://secwatch.observer/filing/0001193125-25-116443.md","text":"https://secwatch.observer/filing/0001193125-25-116443.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525116443/0001193125-25-116443-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525116443/d27625d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T02:00:20.422522+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}